Aragen Bioscience, Inc.
380 Woodview Ave
15 articles with Aragen Bioscience, Inc.
Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a SARS-CoV-2 (COVID 19) Vaccine Candidate
Oragenics, Inc. (NYSE American: OGEN) , (the “Company” or “Oragenics”), today announced, that through its wholly-owned subsidiary, Noachis Terra, it has entered into an agreement with Aragen Bioscience, a leading contract research organization focused on accelerating pre-clinical biologics product development, to advance TerraCov2 the Company’s SARS CoV-2 vaccine candidate. Under the terms of the ag
Avid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution for Cell Line and Process Development through Commercial Manufacturing
Full Service “Sequence-to-Manufacturing” Offering Designed to Drive Efficiencies and Reduce Overall Timelines for Delivering Early-Stage CGMP Bulk Drug Substances
Aragen Bioscience, Inc. and University of Technology, Sydney Enter Into MoU to Support and Accelerate Biologics R&D in Australia
Aragen Bioscience, Inc, a fully owned subsidiary of GVK BIO and a leading large molecule CRO, and University of Technology Sydney, the top-ranked young university in Australia, are pleased to announce a collaboration to accelerate biologics R&D in Australia.
Aragen Bioscience, Inc and Serum Institute of India Pvt. Ltd. are pleased to announce a collaboration for the development of multiple stable cell lines to support Serum’s HIV program.
GVK BIO Announces the Appointment of Axel Schleyer, Ph.D. as Chief Executive Officer, Aragen Bioscience, Inc.
GVK BIO is pleased to announce the appointment of Dr. Axel Schleyer as Chief Executive Officer, Aragen Bioscience Inc.
Aragen Bioscience, Inc. Announces Licensing Agreement For Protein Production Technology From ProteoNic
Aragen Bioscience, Inc. And Transposagen Biopharmaceuticals, Inc. Partner To Launch FUT8 Knockout CHO DG44 Cell Line Development Services
Aragen Bioscience, Inc. and Innovent Biologics Announce Collaboration for Biotherapeutic Product Development
Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Bioscience, Inc.